0937 GMT - Lonza's latest mid-term targets ahead of its capital markets day bode well for the Swiss biotech and chemical company's growth outlook, even if consensus expectations are likely to already have caught up, UBS says. But the update, including a core Ebitda margin of 33%-35% and double-digit growth, is being pushed out to 2024 from 2023, which could imply that margin expansion will be slower than previously thought, the bank says. The forecasts are unlikely to result in material changes to consensus, however, and so the tone of management at the CMD will prove more important to where the shares will head in response, the bank says. UBS maintains a neutral rating. Shares rise 1.3% to CHF703.80. (edward.frankl@dowjones.com)